Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aβ- and tau-associated neuroinflammatory signatures in Alzheimer's disease.

Alzheimer's & dementia (New York, N. Y.)·2026
Same author

Association between automated brain volumetry and visual classification of hippocampal atrophy in MRI.

Neuroimage. Reports·2026
Same author

Tau extent outperforms tau load as a predictor of neurodegeneration in Alzheimer's disease.

Molecular neurodegeneration·2026
Same author

Hypertension acts together with Aβ pathology in late-life to promote memory loss.

The journal of prevention of Alzheimer's disease·2026
Same author

Real-world comparison of brain [<sup>18</sup>F]FDG-PET imaging with CSF Alzheimer's disease biomarkers in a tertiary memory clinic setting.

EClinicalMedicine·2026
Same author

Corrigendum to "The role of cannabinoid ligands in neurodegenerative diseases: Emerging anti-inflammatory, immunomodulation and disease-modifying perspectives" [Pharmacol. Res. 227 (2026) 108185].

Pharmacological research·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Gabriel Colissi Martins1, Christian Limberger1, Gabriel Lermen Hoffmeister1,2

  • 1Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 26, 2025
PubMed
Summary
This summary is machine-generated.

Glial cells like astrocytes and oligodendrocytes may help preserve brain function in Alzheimer's Disease (AD) by compensating for neuronal changes and reducing amyloid-beta (Aβ) burden. This study links higher glial densities to better brain glucose metabolism and lower Aβ accumulation in AD-vulnerable regions.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neuroscience
  • Neuroimaging
  • Cell Biology

Background:

  • Neurons and glial cells (astrocytes, microglia, oligodendrocytes) are crucial for synaptic function.
  • Alzheimer's Disease (AD) pathogenesis, including amyloid-beta (Aβ) accumulation, disrupts cell function and leads to brain hypometabolism, a marker of neurodegeneration.
  • Understanding the relationship between cell densities and AD progression is vital.

Purpose of the Study:

  • To investigate how brain cellular densities associate with FDG-PET (glucose metabolism) and Aβ-PET imaging.
  • To examine these associations across brain regions vulnerable and non-vulnerable to AD.

Main Methods:

  • Utilized FDG- and Aβ-PET images from 619 cognitively unimpaired (CU) and impaired (CI) individuals from the ADNI database.
  • Sourced brain cellular abundance maps from the Neuropm-Lab's GitHub repository.
  • Performed Pearson correlations between cellular densities and mean standardized uptake value ratio (SUVr) for FDG and Aβ across specified brain regions.

Main Results:

  • Neuronal density positively correlated with FDG-PET in non-vulnerable regions, but negatively with delta FDG SUVr in both vulnerable and non-vulnerable regions for amyloid-positive (A+) individuals.
  • Astrocyte density positively correlated with delta FDG-PET SUVr in vulnerable regions and showed positive correlations in all groups for Aβ-PET in vulnerable regions.
  • Oligodendrocyte density showed a positive correlation with FDG-PET in vulnerable regions, irrespective of amyloid or cognitive status.

Conclusions:

  • Higher astrocyte densities correlate with reduced differences in brain glucose metabolism (delta FDG SUVr) in AD-vulnerable regions, suggesting a compensatory role.
  • Oligodendrocytes show positive correlations with FDG-PET, further supporting a glial contribution to maintaining brain metabolism.
  • Increased astrocyte density is linked to lower amyloid burden in vulnerable brain regions, highlighting glia's role in modulating amyloid pathology.